{"id":"W2883673963","doi":"10.1016/s1470-2045(18)30343-7","title":"Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":137,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université de Montréal","funders":"National Cancer Institute; AstraZeneca","keywords":"Medicine; Internal medicine; Olaparib; Tolerability; Quality of life (healthcare); Placebo; Clinical endpoint; Oncology; Ovarian cancer; Adverse effect; Nausea; Progression-free survival; Randomized controlled trial; Cancer; Chemotherapy; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008197259,0.0002902049,0.001977123,0.0001204183,0.00009632932,0.00001311709,0.00007063522,0.0001834919,0.00008434101],"category_scores_gemma":[0.0002976791,0.0001692157,0.00005929121,0.0002432464,0.000670123,0.00008835647,0.00002062872,0.0003550234,0.000001437743],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000284034,"about_ca_system_score_gemma":0.0005138154,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006273598,"about_ca_topic_score_gemma":0.001027921,"domain_scores_codex":[0.9968846,0.0009253595,0.0009991764,0.0004320624,0.0003135543,0.0004452661],"domain_scores_gemma":[0.9973835,0.0008168407,0.001026825,0.000341449,0.0002831665,0.0001482289],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9476436,0.000758966,0.03250853,0.00005692126,0.0005440543,0.00001247684,0.01053048,0.000006534058,0.0001360229,0.00005332873,0.0002655225,0.007483558],"study_design_scores_gemma":[0.8686193,0.008130614,0.1216933,0.0002157787,0.00007613471,0.00001274307,0.0004667967,0.0001803216,0.0001560703,0.00006919899,0.0001988599,0.0001808434],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9821107,0.0003105651,0.00007725537,0.01171437,0.0001865228,0.005222136,0.00009860895,0.00004010319,0.0002396917],"genre_scores_gemma":[0.9922023,0.0001042626,0.0005747293,0.006219851,0.000132713,0.0006526342,0.00002925243,0.00003492708,0.00004934251],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08918478,"threshold_uncertainty_score":0.6900415,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02878310592264365,"score_gpt":0.3335244201553895,"score_spread":0.3047413142327459,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}